TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23047003

Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens correction
Number of subjects: 114
Study: 21357811

Group type: EXPERIMENTAL
Intervention: REACH VA intervention (6-month program with 12 individual in-home and telephone sessions and 5 telephone support group sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REACH VA intervention
Number of subjects: 0
Study: 19678713

Group type: EXPERIMENTAL
Intervention: Alitretinoin 10 mg/day
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg/day
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1032
Study: 16861404

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study: 15309453

Group type: EXPERIMENTAL
Intervention: Low dose soy protein product with added beta-sitosterol (10 g once daily)
Number of subjects: 36
Study: 10831195

Group type: EXPERIMENTAL
Intervention: bupivacaine-fentanyl (BF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: bupivacaine-morphine (BM)
Number of subjects: 60
Study: 9251504

Group type: EXPERIMENTAL
Intervention: Toborinone at 5 micrograms.kg‐1.min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toborinone at 10 micrograms.kg‐1.min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toborinone at 15 micrograms.kg‐1.min‐1
Number of subjects: 0
Study: 8465408

Group type: EXPERIMENTAL
Intervention: Albendazole 600 mg
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg for 3 days
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg for 5 days
Number of subjects: 678

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 678
Study: 3516397

Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: BAFMi (carmustine, doxorubicin, 5-FU, and mitomycin)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: BAFMi
Number of subjects: 82
Study: 30928954

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily
Number of subjects: 190

Group type: COMPARATOR
Intervention: Voglibose 0.2 mg three times daily
Number of subjects: 190
Study: 29384854

Group type: EXPERIMENTAL
Intervention: UAE combined with MTX
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: UAE combined with MTX and 5-FU
Number of subjects: 100
Study: 26694848

Group type: EXPERIMENTAL
Intervention: Exercise group (light-moderate intensity aerobic and strength exercises, 3 sessions/week for 55-60 min from weeks 9-11 to 38-39)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 241
Study: 25342184

Group type: EXPERIMENTAL
Intervention: 2% sodium bicarbonate-buffered lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no anesthetic)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 22956826

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered simultaneously with targets of varying contrast, with a single TMS pulse; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No adaptation (control condition)
Number of subjects: 0
Study: 20157323

Group type: EXPERIMENTAL
Intervention: Taranabant 2 mg
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: Taranabant 4 mg
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1256
Study: 17629631

Group type: EXPERIMENTAL
Intervention: tiagabine (20 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 141
Study: 16269957

Group type: EXPERIMENTAL
Intervention: Low-dose felodipine (extended release)
Number of subjects: 9800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9800
Study: 12505245

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d)
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Biomarker DHT
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Pill counts as a gold standard
Number of subjects: 18000
Study: 10562259

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 5674

Group type: COMPARATOR
Intervention: Therapeutic bivalirudin anticoagulation
Number of subjects: 5674
Study: 8700313

Group type: COMPARATOR
Intervention: Postoperative flomoxef administration with saline containing no antibiotics for irrigation (Group A)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: New protocol of flomoxef and saline containing gentamicin for irrigation (Group B)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Continuation of the new protocol (Group C)
Number of subjects: 286
Study: 2012420

Group type: EXPERIMENTAL
Intervention: 7.2% NaCl solution prepared in hydroxyethylstarch (HES) solution (HS‐HES group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6% HES 200/0.5 solution (HES group)
Number of subjects: 30
Study: 7026094

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) given for 3 months at weekly intervals
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 27
Study: 29658430

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-L1 positive subgroup)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Placebo (PD-L1 positive subgroup)
Number of subjects: 1019
Study: 28893415

Group type: EXPERIMENTAL
Intervention: dCRT + cetuximab
Number of subjects: 258

Group type: COMPARATOR
Intervention: dCRT
Number of subjects: 258
Study: 26166613

Group type: EXPERIMENTAL
Intervention: Monitoring of fraction of exhaled nitric oxide (FENO) and sputum eosinophils
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clinical score based treatment (control group)
Number of subjects: 28
Study: 24624781

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with fractionated dose (1 Gy + 1.5 Gy or 1 Gy + 2 Gy with 4‐hour intervals to a focal dose of 60 Gy)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (2 Gy 5 times a week)
Number of subjects: 257
Study: 21695447

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 18435369

Group type: EXPERIMENTAL
Intervention: Brushing before erosion (A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Brushing after erosion (B)
Number of subjects: 10
Study: 16931658

Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus followed by 1.75 mg x kg(‐1) x h(‐1) continuous infusion)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Heparin-protamine
Number of subjects: 101
Study: 12075575

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED) and behaviour modification
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study: 9443697

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 143

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 143

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 143
Study: 7621842

Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg (maximum cumulative dose 0.3 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2229490

Group type: EXPERIMENTAL
Intervention: Topical tretinoin (retinoic acid)
Number of subjects: 30
Study: 798468

Group type: EXPERIMENTAL
Intervention: Pimozide administered in a single daily dose
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlordiazepoxide administered in divided daily doses
Number of subjects: 18
Study: 6454632

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no secretory inhibitors)
Number of subjects: 0
Study: 31471400

Group type: EXPERIMENTAL
Intervention: Primary surgery
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Palliative treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Complete tumor removal at surgery
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Complication rate
Number of subjects: 110
Study: 29991814

Group type: EXPERIMENTAL
Intervention: Vaping with nicotine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham vaping
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vaping without nicotine
Number of subjects: 25
Study: 26567260

Group type: EXPERIMENTAL
Intervention: Hungry state
Number of subjects: 78

Group type: COMPARATOR
Intervention: Satiated state (after sweet lunch)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Satiated state (after savory lunch)
Number of subjects: 78
Study: 23808817

Group type: EXPERIMENTAL
Intervention: Extended nutrition care (telephone dietary counselling for up to 100 days post-transplantation)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual nutrition care (no further nutrition support after hospital discharge)
Number of subjects: 37
Study: 22595385

Group type: EXPERIMENTAL
Intervention: Positive fluid balance (PosFB) group (median 849 ml, IQR 328 - 1,552 ml, n = 19)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High positive fluid balance (highPosFB) group (n = 10)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High positive fluid balance (highPosFB) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Negative fluid balance (NegFB) group (median -1,221 ml, IQR -1,974 to -653 ml, n = 71)
Number of subjects: 90
Study: 19944357

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1587
Study: 17715208

Group type: EXPERIMENTAL
Intervention: Cortisol 20 mg orally twice daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15494456

Group type: EXPERIMENTAL
Intervention: 0.3 mg recombinant human TSH (rhTSH)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 12403289

Group type: EXPERIMENTAL
Intervention: Educational strategy including dissemination of evidence-based guidelines via a problem-based interactive workshop facilitated by an opinion leader and a laminated algorithm and guidelines.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 62
Study: 10546016

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 54
Study: 8703492

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted controlled blood reperfusion (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No leukocyte depletion (Group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted controlled blood reperfusion (Group C)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No leukocyte depletion (Group D)
Number of subjects: 34
Study: 2110064

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 477470

Group type: EXPERIMENTAL
Intervention: 4-methylumbelliferone (hymecromone)
Number of subjects: 50
Study: 30896330

Group type: EXPERIMENTAL
Intervention: Natural pain reliever
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Experimental condition with rational appeal
Number of subjects: 1125
Study: 29200411

Group type: EXPERIMENTAL
Intervention: Bicyclol 25 mg three times daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine 456 mg three times daily
Number of subjects: 168
Study: 24777702

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device with heel support and vibrating device for 1 week
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group treated with only a CPM device
Number of subjects: 144
Study: 23801836

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 200

Group type: COMPARATOR
Intervention: Midazolam-fentanyl
Number of subjects: 200
Study: 21730925

Group type: EXPERIMENTAL
Intervention: Intrathecal atropine 100 µg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intravenous atropine 100 µg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Saline only (control group)
Number of subjects: 204
Study: 19998580

Group type: EXPERIMENTAL
Intervention: Test formulation (70 mg alendronate sodium)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Reference formulation (70 mg alendronate sodium)
Number of subjects: 122
Study: 17518171

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA) with metamizole and tramadol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous infusion by elastomeric pump of the same analgesic solution (metamizole and tramadol)
Number of subjects: 50
Study: 15595587

Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1) suxamethonium
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.6 mg kg(‐1) rocuronium after suxamethonium
Number of subjects: 30
Study: 12490125

Group type: EXPERIMENTAL
Intervention: Intramuscularly administered polysaccharide nucleic acid fraction of Bacillus Calmette Guerin (PSN-BCG)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Anti-tuberculous therapy and thoracentesis
Number of subjects: 2
Study: 10095972

Group type: EXPERIMENTAL
Intervention: Intermenstrual bleeding since last menses
Number of subjects: 2625

Group type: EXPERIMENTAL
Intervention: Excessive menstrual flow
Number of subjects: 2625
Study: 7806600

Group type: EXPERIMENTAL
Intervention: Indocid capsules 'A' (75 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Indogesic tablets 'B' (75 mg)
Number of subjects: 22
Study: 2528260

Group type: EXPERIMENTAL
Intervention: Azelaic acid (20%)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Hydroquinone (2%)
Number of subjects: 155
Study: 989399

Group type: EXPERIMENTAL
Intervention: 500 mg tybamate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg secobarbital
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30482218

Group type: EXPERIMENTAL
Intervention: Dietary Screener Questionnaire (DSQ)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Automated Self-Administered 24-Hour Recalls for Children (ASA24-Kids)
Number of subjects: 656
Study: 28663382

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NaNO3) ingestion (9.3 mg/kg body weight)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (NaCl, 8.8 mg/kg body weight)
Number of subjects: 17
Study: 25625260

Group type: EXPERIMENTAL
Intervention: Propofol infusion (starting at 300 µg kg·min) with oxygen via nasal cannula
Number of subjects: 150

Group type: COMPARATOR
Intervention: Isoflurane with 70% N2O in oxygen delivered via LMA
Number of subjects: 150
Study: 23506279

Group type: EXPERIMENTAL
Intervention: Active treatment (soft tissue massage for 60 seconds)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control treatment (crowns of the mandibular premolar teeth massaged)
Number of subjects: 38
Study: 21392690

Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 41
Study: 19046094

Group type: EXPERIMENTAL
Intervention: Antioxidants (2 capsules of Nature Made antioxidants 2 hours before, and 2 and 8 hours after ESWL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Antioxidants (2 capsules of antioxidants at 2 and 8 hours after ESWL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no antioxidants, n=39)
Number of subjects: 120
Study: 16612143

Group type: EXPERIMENTAL
Intervention: 1% ciclopiroxolamine cream applied twice daily for 28 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 28 days
Number of subjects: 50
Study: 14702997

Group type: EXPERIMENTAL
Intervention: Fatigued participants
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fatigued participants with low computer experience
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Highly experienced participants
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (nonfatigued) participants
Number of subjects: 68
Study: 10780140

Group type: EXPERIMENTAL
Intervention: Obese with medical information explaining the obesity
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Obese
Number of subjects: 184

Group type: COMPARATOR
Intervention: Average-weight
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Same-sex target child
Number of subjects: 184
Study: 9060219

Group type: EXPERIMENTAL
Intervention: Halofantrine schedule II (three doses of 500 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Halofantrine (all schedules)
Number of subjects: 120
Study: 1900485

Group type: EXPERIMENTAL
Intervention: Mesterolone (150 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 6401379

Group type: EXPERIMENTAL
Intervention: 5 g L-lysine orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: No lysine load or other amino acids (tryptophan or threonine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Undernourished subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitation of undernourished subjects
Number of subjects: 0
Study: 31542291

Group type: EXPERIMENTAL
Intervention: Antibiotic or silver shunts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ventriculoperitoneal shunts
Number of subjects: 0
Study: 29521263

Group type: EXPERIMENTAL
Intervention: Manosar® (D-mannose 2 g, 24h prolonged release, associated with Proanthocyanidin (PAC) 140 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: PAC (240 mg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Manosar®
Number of subjects: 93

Group type: COMPARATOR
Intervention: PAC
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study: 28660416

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 26181707

Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ritonavir (RTV)
Number of subjects: 100
Study: 24143917

Group type: EXPERIMENTAL
Intervention: High current intensity group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low current intensity group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mosapride citrate control group
Number of subjects: 0
Study: 22238838

Group type: EXPERIMENTAL
Intervention: Headache presence
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Headache among Blacks
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Headache among Caucasians
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Anxiety and depressive symptoms
Number of subjects: 1073
Study: 18629725

Group type: EXPERIMENTAL
Intervention: Low level of concern about post-cessation weight gain
Number of subjects: 412

Group type: COMPARATOR
Intervention: High level of concern about post-cessation weight gain
Number of subjects: 412
Study: 16838818

Group type: COMPARATOR
Intervention: drugs only (nicotine replacement therapy patch, nasal spray, inhaler, and Zyban)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: drugs and counseling (drugs and proactive telephone counseling)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: drugs if counseling (drugs conditional on enrollment in counseling)
Number of subjects: 393
Study: 14740589

Group type: EXPERIMENTAL
Intervention: Bilateral interpleural analgesia (IP) using bupivacaine 0.5% (0.8 mg/kg) and 2 mg morphine diluted to 50 ml saline for each side
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lumbar epidural analgesia (EP) using the same mixture diluted in 20 ml saline injected in the epidural space (L2-3)
Number of subjects: 30
Study: 10936119

Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg bid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 microg bid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9010086

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Gd-DTPA MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiograms
Number of subjects: 0
Study: 7956274

Group type: EXPERIMENTAL
Intervention: Platelet-activating factor receptor antagonist (BN 52021) 120 mg intravenously every 12 hrs for 4 days
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Platelet-activating factor receptor antagonist (BN 52021)
Number of subjects: 262
Study: 3677280

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg IV)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 7
Study: 29351097

Group type: EXPERIMENTAL
Intervention: High-rate epidural bolus (300 ml/h)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Low-rate epidural bolus (100 ml/h)
Number of subjects: 210
Study: 27027886

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study: 24419306

Group type: EXPERIMENTAL
Intervention: Emotional awareness training (EMT) in addition to standard symptom‐oriented medical treatment; included two emotion awareness training sessions and daily emotion recording over 20 months.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard symptom‐oriented medical treatment (MT group) only.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emotional awareness training (EMT) in addition to standard symptom‐oriented medical treatment.
Number of subjects: 100